Jinxin Fertility Group Ltd. (1951) AI Stock Analysis

• Market Cap: HK$8.10B
• Dividend Yield: 2.02%
• Average Volume (3M): 45.77M
• Price to Earnings (P/E): 25.8
• Beta (1Y): 1.41
• Revenue Growth: -1.04%
• EPS Growth: -20.43%
• Country: HK
• Employees: 3,198
• Sector: Healthcare
• Sector Strength: 58
• Industry: Medical - Care Facilities
• EPS (TTM): 0.11
• Shares Outstanding: 2,757,706,000
• 10 Day Avg. Volume: 55,068,884
• 30 Day Avg. Volume: 45,774,546
• PEG Ratio: -2.01
• Price to Book (P/B): 1.84
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -38.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$4.35
• Price Target Upside: 47.46% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 70 Outperform
• Price Target: HK$3.00 ▲(1.69%Upside)

Jinxin Fertility Group's overall stock score of 70 reflects its strong financial performance, characterized by consistent revenue growth and solid balance sheet metrics. The technical analysis indicates a stable but neutral market position, while valuation metrics suggest the stock is fairly valued. The absence of earnings call data and corporate events limits further insight into the company's current strategic direction.

Jinxin Fertility Group Ltd. Business Overview & Revenue Model

Company Description

Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and the United States. The company primarily offers two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. It also provides related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; medical services in the areas of gynecology, urology, and internal medicine; ambulatory surgery center facilities services; and ancillary medical services. Further, it offers pre-implantation genetic screening testing services; and engages in the investment management and management consultancy, and real estate development and operation activities. Jinxin Fertility Group Limited was founded in 2003 and is headquartered in Chengdu, China.

How the Company Makes Money

Jinxin Fertility Group Ltd. generates revenue primarily through its assisted reproductive services, with in vitro fertilization (IVF) being the core service offering. The company earns money by providing a range of fertility treatments, which include medical consultations, diagnostic services, laboratory procedures, and the actual IVF processes. Additionally, Jinxin Fertility may have partnerships with hospitals and clinics, enhancing its service reach and client base. Revenue is largely driven by the demand for fertility services in China and potentially in other regions where the company operates, supported by factors such as increasing infertility rates, advancements in reproductive technology, and growing social acceptance of assisted reproductive techniques.

Jinxin Fertility Group Ltd. Financial Statement Overview

Summary

Jinxin Fertility Group demonstrates a strong financial position with consistent revenue growth, solid profitability, and efficient cash flow management. The balance sheet shows prudent leverage and strong equity, while operational efficiency is reflected in healthy margins and cash flow metrics.

Income Statement

Jinxin Fertility Group has shown consistent revenue growth over the years, with a notable increase in total revenue from 2020 to 2024. The gross profit margin has slightly decreased recently, indicating rising costs or pricing pressures. However, the company maintains healthy EBIT and EBITDA margins, demonstrating efficient operations and profitability.

Balance Sheet

The company has a strong equity base with a favorable debt-to-equity ratio, indicating prudent financial leverage. The return on equity remains strong, reflecting effective use of shareholders' funds. The equity ratio has increased over the years, highlighting a solid financial foundation and asset management.

Cash Flow

Operating cash flow has been positive and growing, supporting ongoing operations. The free cash flow, although fluctuating, has improved recently, enhancing financial flexibility. The operating cash flow to net income ratio is robust, indicating strong cash earnings conversion.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.81B	2.79B	2.36B	1.84B	1.43B
	Gross Profit
1.10B	1.18B	913.13M	771.48M	565.78M
	EBIT
441.58M	480.47M	285.37M	371.38M	237.68M
	EBITDA
645.06M	682.02M	476.21M	494.08M	331.91M
	Net Income Common Stockholders
283.10M	344.72M	121.12M	339.90M	251.62M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
570.82M	852.90M	1.40B	1.93B	2.47B
	Total Assets
14.98B	14.90B	15.23B	12.83B	9.16B
	Total Debt
2.71B	2.55B	4.16B	2.09B	406.87M
	Net Debt
2.17B	1.93B	2.83B	1.23B	-274.75M
	Total Liabilities
4.63B	4.71B	6.50B	4.07B	1.70B
	Stockholders Equity
10.27B	10.09B	8.64B	8.55B	7.28B
Cash Flow		Free Cash Flow
489.30M	510.92M	-417.65M	263.62M	41.89M
	Operating Cash Flow
629.20M	684.48M	541.74M	343.45M	308.04M
	Investing Cash Flow
-293.27M	-375.04M	-1.38B	-1.57B	1.15B
	Financing Cash Flow
-458.29M	-950.45M	460.14M	955.05M	-55.58M

Jinxin Fertility Group Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.95
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1951, the sentiment is Positive. The current price of 2.95 is above the 20-day moving average (MA) of 2.88, below the 50-day MA of 2.96, and above the 200-day MA of 2.90, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 54.04 is Neutral, neither overbought nor oversold. The STOCH value of 53.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1951.

Jinxin Fertility Group Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1951	70 Outperform	HK$8.10B	25.76	2.78%	2.02%	-1.04%	-20.43%
Sector *	54 Neutral	$5.37B	3.26	-45.10%	3.30%	16.81%	0.02%
KWGPF		$139.28M	―	-95.62%	―	―	―
PANHF		$2.14B	95.34	0.96%	―	―	―
TRSBF		$7.12B	25.54	14.19%	1.13%	―	―
5C3		€152.02M	―	-5.63%	10.21%	―	―
6086	41 Neutral		―		―	―	―

Jinxin Fertility Group Ltd. Corporate Events

Jinxin Fertility Group Announces 2025 Annual General Meeting

Jinxin Fertility Group Ltd. has announced its upcoming annual general meeting scheduled for June 26, 2025, in Chengdu, China. The meeting will address several key resolutions, including the adoption of the 2024 financial statements, re-election of directors, and re-appointment of Deloitte Touche Tohmatsu as auditors. Additionally, the company seeks shareholder approval to authorize the board to issue new shares and fix director remuneration, indicating a focus on strategic growth and governance.

The most recent analyst rating on (HK:1951) stock is a Buy with a HK$3.33 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.

Jinxin Fertility Group Reports Revenue Growth but Decline in Profits for 2024

Jinxin Fertility Group Ltd. reported a slight increase in revenue for the year ending December 31, 2024, reaching approximately RMB2,811.6 million, a 0.8% rise from the previous year. However, the company’s net profit saw a significant decline of 21.2% to RMB273.5 million. The board decided not to recommend a final dividend for the year, reflecting the financial challenges faced. The company provided non-IFRS financial measures to offer a clearer picture of its operational performance, despite the declines in adjusted net profit and EBITDA.

Jinxin Fertility Group Redesignates Mr. Zhong Yong as Non-Executive Director

Jinxin Fertility Group Limited has announced the redesignation of Mr. Zhong Yong from an executive director to a non-executive director, effective March 28, 2025. Mr. Zhong will continue to serve as the Chairman of the Board and contribute to the company’s strategic planning, reflecting a strategic reallocation of duties within the group. This move underscores the company’s commitment to leveraging Mr. Zhong’s expertise in guiding its corporate strategies and development.

Jinxin Fertility Group Announces Board Composition and Committee Roles

Jinxin Fertility Group Limited has announced the composition of its board of directors and the roles within its five established committees. This announcement provides clarity on the leadership structure and governance, which is crucial for stakeholders to understand the company’s strategic direction and operational oversight.